TOLREMO therapeutics
Z├╝rich
About TOLREMO therapeutics
TOLREMO therapeutics is a developer of small molecules intended to target novel drug resistance pathways in cancer therapy.The company's molecules specifically eradicate those cancer cells that cause drug resistance, enabling physicians to get personalized anti-drug resistance therapies to meaningfully prolong the lives of cancer patients.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $54.7M
- Funding stage: Early Stage Venture
- Last round: Series A (Sep 2023)
- Website: tolremo.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/tolremo-therapeutics-38800 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.